Results 1 to 10 of about 231,458 (256)

Case Report: Bispecific CD20/CD30-targeted chimeric antigen receptor T-cell therapy for non-Hodgkin’s lymphoma [PDF]

Frontiers in Immunology
CD19-directed CAR T-cell therapy is a breakthrough immunotherapy for B-cell malignancies. However, CD19 loss-mediated relapsed/refractory disease continues to pose a significant challenge, highlighting the urgent need for CAR T cells targeting ...
Yuejiao Huang, Yiming Gong, Xiang Liu, Huaying Ruan, Jinhua Lu, Hosein Kouros-Mehr, Hong Liu, Han Wang   +7 more
doaj   +2 more sources

Anti-CD20 Immunoglobulin G Radiolabeling with a 99mTc-Tricarbonyl Core: In Vitro and In Vivo Evaluations. [PDF]

PLoS ONE, 2015
In recent years, the diagnostic and therapeutic uses of radioisotopes have shown significant progress. Immunoglobulin (Ig) appears to be a promising tracer, particularly due to its ability to target selected antigens.
Hélène Carpenet, Armelle Cuvillier, Jacques Monteil, Isabelle Quelven   +3 more
doaj   +2 more sources

CD20-positive peripheral T-cell lymphoma not otherwise specified: a case series and review of the literature

Frontiers in Oncology
Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) is a heterogeneous and aggressive malignancy that usually lacks B-cell associated antigens.
Pan Zhou, Lifu Wang, Xiaohang Pei, Liu Yang, Yunmeng Zhou, Rongjun Ma, Yuqing Chen, Zunmin Zhu, Xiaoli Yuan   +8 more
doaj   +1 more source

The Influence of B Cell Depletion Therapy on Naturally Acquired Immunity to Streptococcus pneumoniae

Frontiers in Immunology, 2021
The anti-CD20 antibody Rituximab to deplete CD20+ B cells is an effective treatment for rheumatoid arthritis and B cell malignancies, but is associated with an increased incidence of respiratory infections.
Giuseppe Ercoli, Elisa Ramos-Sevillano, Rie Nakajima, Rafael Ramiro de Assis, Algis Jasinskas, David Goldblatt, Philip Felgner, Gisbert Weckbecker, Jeremy Brown   +8 more
doaj   +1 more source

Causal effects of immune cell surface antigens and functional outcome after ischemic stroke: a Mendelian randomization study

Frontiers in Immunology
ObjectiveWhile observational studies link immune cells with post-stroke functional outcome, the underlying immune mechanisms are not well understood.
Weiming Sun, Weiming Sun, Weiming Sun, Jiawei Gui, Keqi Wan, Keqi Wan, Yize Cai, Xiangli Dong, Guohua Yu, Guohua Yu, Chafeng Zheng, Chafeng Zheng, Zhen Feng, Zhen Feng, Zhen Feng, Lang Shuai, Lang Shuai   +16 more
doaj   +1 more source

Análise da rejeição do transplante de aponeurose em coelhos

Einstein (São Paulo)
OBJETIVO: Estudar a viabilidade de aponeurose heteróloga para fechar parede abdominal de coelhos, com ênfase no processo de rejeição. MÉTODOS: Este projeto foi aprovado pelo Comitê de Cuidados Animais da Faculdade de Ciências Médicas da Santa Casa de São
Andre Ibrahim David, Eduardo Sauerbronn Gouvea, Felipe Ribeiro Batista, Paulo Henrique Fogaça de Barros, Dino Martini Filho, Victor Arias, Paulo Roberto Corsi, Luiz Arnaldo Szutan   +7 more
doaj   +1 more source

A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines

Journal for ImmunoTherapy of Cancer, 2017
Background Clinical success with chimeric antigen receptor (CAR)- based immunotherapy for leukemia has been accompanied by the associated finding that antigen-escape variants of the disease are responsible for relapse.
Dina Schneider, Ying Xiong, Darong Wu, Volker Nӧlle, Sarah Schmitz, Waleed Haso, Andrew Kaiser, Boro Dropulic, Rimas J. Orentas   +8 more
doaj   +1 more source

Anti-CD22/CD20 Bispecific antibody with enhanced trogocytosis for treatment of Lupus. [PDF]

PLoS ONE, 2014
The humanized anti-CD22 antibody, epratuzumab, has demonstrated therapeutic activity in clinical trials of lymphoma, leukemia and autoimmune diseases, treating currently over 1500 cases of non-Hodgkin lymphoma, acute lymphoblastic leukemias, Waldenström ...
Edmund A Rossi, Chien-Hsing Chang, David M Goldenberg   +2 more
doaj   +1 more source

Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting

Molecular Oncology
Development of chimeric antigen receptor T‐cell therapy has revolutionized the treatment of B‐cell malignancies, although challenges such as antigen escape and tumor heterogeneity often decrease treatment success. Modular CARs targeting multiple antigens
Pablo Gonzalez‐Garcia, Noelia Moares, Wenjie Yi‐He, Rosa Luna‐Espejo, Ricardo Fernandez‐Cisnal, Javier Ocaña‐Cuesta, Juan P. Muñoz‐Miranda, Antonio Gabucio, Cecilia M. Fernandez‐Ponce, Francisco Garcia‐Cozar   +9 more
doaj   +1 more source

Immunotherapy for B-cell lymphoma: current status and prospective advances

Frontiers in Immunology, 2012
Therapy for non-Hodgkin's lymphoma has progressed significantly over the last decades. However, the majority of patients remain incurable, and novel therapies are needed.
Nurit eHollander
doaj   +1 more source